Chong Kun Dang Signs Nesp Biosimilar Deal In Persian Gulf

Deal With Oman-Based Menagen Expands Access To Darbepoetin Alfa

 
• By Dean Rudge

Chong Kun Dang’s Nesbell (darbepoetin alfa) biosimilar is set to head to the Persian Gulf under a technology transfer and commercialization agreement with Oman-based Menagen Pharmaceutical Industries.

Medicine on Saudi Arabia money, banknotes detailed background photo texture, health insurance, medical concept - Image
Menagen has a manufacturing facility in Muscat • Source: Shutterstock

More from Biosimilars

More from Products